16E Stock Overview A medical device company, designs and manufactures implants and surgical instruments in Germany, Sweden, rest of Europe, the United States, and internationally. More details
Rewards Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Episurf Medical AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for Episurf Medical Historical stock prices Current Share Price SEK 0.0003 52 Week High SEK 0.10 52 Week Low SEK 0.0001 Beta 1.01 1 Month Change -90.00% 3 Month Change 200.00% 1 Year Change -99.58% 3 Year Change -99.92% 5 Year Change -99.69% Change since IPO -99.90%
Recent News & Updates
Independent Chairman of the Board recently bought €16k worth of stock Nov 10
Episurf Medical AB (publ) to Report Fiscal Year 2024 Results on Mar 06, 2025 Oct 29
Third quarter 2024 earnings released: kr0.024 loss per share (vs kr0.078 loss in 3Q 2023) Oct 26 Episurf Medical AB (publ) to Report Q2, 2025 Results on Jul 11, 2025
Chief Executive Officer recently bought €201k worth of stock Sep 26
New major risk - Market cap size Sep 24 See more updates
Independent Chairman of the Board recently bought €16k worth of stock Nov 10
Episurf Medical AB (publ) to Report Fiscal Year 2024 Results on Mar 06, 2025 Oct 29
Third quarter 2024 earnings released: kr0.024 loss per share (vs kr0.078 loss in 3Q 2023) Oct 26 Episurf Medical AB (publ) to Report Q2, 2025 Results on Jul 11, 2025
Chief Executive Officer recently bought €201k worth of stock Sep 26
New major risk - Market cap size Sep 24
Second quarter 2024 earnings released: kr0.03 loss per share (vs kr0.11 loss in 2Q 2023) Jul 14
New major risk - Shareholder dilution Jun 25 Episurf Medical AB (publ) has completed a Composite Units Offering in the amount of SEK 90.158983 million. Jun 14
Insufficient new directors Jun 02
First quarter 2024 earnings released: kr0.077 loss per share (vs kr0.087 loss in 1Q 2023) Apr 25
New major risk - Market cap size Apr 22
Full year 2023 earnings released: kr0.35 loss per share (vs kr0.29 loss in FY 2022) Mar 12
Full year 2023 earnings released: kr0.35 loss per share (vs kr0.29 loss in FY 2022) Feb 11
Episurf Medical AB (Publ) Receives Four Additional Patent Approval Notification Nov 29
Third quarter 2023 earnings released Oct 29 Episurf Medical AB (publ), Annual General Meeting, Apr 09, 2024
Episurf Medical Announces 510(k) Submission for Big Toe Implant Oct 20
Episurf Members Announces Nomination Committee for Episurf Medical's Annual General Meeting in 2024 Oct 17
Episurf Medical Announces Early Clinical Results from Episealer Talus Study Presented at Scientific Congress Sep 28
Episurf Medical Announces Prospective Episealer Talus Clinical Study Sep 14
Episurf Medical AB (publ) Announces First Commercial Case in the US Has Been Scheduled for Surgery Aug 23
Second quarter 2023 earnings released Jul 14
Chief Executive Officer recently bought €59k worth of stock May 10
First quarter 2023 earnings released May 01
Chief Executive Officer recently bought €6.5k worth of stock Feb 27
Full year 2022 earnings released: kr0.29 loss per share (vs kr0.31 loss in FY 2021) Feb 18
Episurf Medical AB (publ), Annual General Meeting, May 04, 2023 Feb 17
Episurf Medical AB (publ) Announces Dennis Stripe Not Stand for Re-Election as Chairman of the Board of Directors Feb 13
Episurf Medical AB (Publ) Receives Notice of Allowance from the United States Patent and Trademark Office Feb 03
Episurf Medical AB (publ) Receives FDA 510(k) clearance for Episealer® Patellofemoral System Dec 26
Third quarter 2022 earnings released Nov 18 Episurf Medical AB (publ) to Report Fiscal Year 2023 Results on Feb 09, 2024
Episurf Medical Announces That the Episealer® Knee Technology and Clinical Results Nov 11
Episurf Medical AB (Publ) Appoints Nomination Committee Oct 15
Episurf Medical AB (Publ) Provides Update on 510(K) Application to FDA for the Episealer Patellofemoral System Sep 21
Episurf Medical Announces New U.S. Patent Approval for Episurf Medical Aug 20
Episurf Medical AB (Publ) Announces New Patent Approval in Hong Kong for Episurf Medical Aug 18
Episurf Medical Announces Results from Study with Episealer® Knee Implant Accepted for Presentation at Swedish Orthopaedic Congress Aug 16
Episurf Medical AB (Publ) Announces New Patent Approval in Hong Kong Jul 21
Second quarter 2022 earnings released Jul 16
Episurf Medical AB (Publ) Announces First Surgery in India with the Knee Implant Episealer® Has Been Scheduled Jun 29
First quarter 2022 earnings released May 01
Episurf Medical Provides Updates of 510(K) Application on Episealer Patellofemoral System Apr 25
New European Patent Approves for Episurf Medical Apr 20 Episurf Medical AB (Publ) Announces the Initiation of a Prospective Investigator-Initiated Study with 2 Years Follow-Up of 25 Episealer Talus Patients
First Indian Patent Approval for Episurf Medical Apr 06
Episurf Medical Receives Reimbursement Coverage for Episealer Talus in Belgium Feb 24
Episurf Medical AB’s Implants Receive National Regulatory Approval in Hong Kong Feb 19
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 12
The European Patent Office Approves European Patent for Episurf Medical Feb 03
the European Patent Office EPO Announces Its Intention to Grant Another European Patent for Episurf Medical AB (publ) Jan 18
Episurf Medical Submits 510(K) Application for Episealer® Patellofemoral System Dec 31
Board Member recently bought €78k worth of stock Dec 15
Third quarter 2021 earnings released Oct 30
Episurf Medical AB (Publ) Announces Results from Multicentre Study Sep 02
Independent Chairman of the Board recently bought €5.8k worth of stock Aug 30
Independent Chairman of the Board recently bought €5.8k worth of stock Aug 27
Episurf Medical Announces the Initiation of Prospective Investigator-Initiated European Multicentre Study with 5 Years' Follow-Up of 25 Episealer® Talus Patients Jul 24
Second quarter 2021 earnings released: kr0.08 loss per share (vs kr0.084 loss in 2Q 2020) Jul 18
Episurf Medical AB (Publ) Announces Update on Episealer Patellofemoral System for the Us Market Jul 16
Episurf Medical Announces Initiation of an Investigator-Initiated European Multicentre Study with 5 Years’ Follow-Up of 50 Episealer® Knee Patients Jun 25
Independent Director has left the company May 20
First quarter 2021 earnings released May 01
Full year 2020 earnings released: kr0.39 loss per share (vs kr1.04 loss in FY 2019) Apr 05
CEO & Sales Director recently bought €11k worth of stock Mar 03
New 90-day high: €0.34 Feb 23
Full year 2020 earnings released: kr0.34 loss per share (vs kr1.04 loss in FY 2019) Feb 20
Revenue beats expectations Feb 20 Episurf Medical AB (publ), Annual General Meeting, May 10, 2021
Episurf Medical AB (Publ) Intends to Submit A 510(K) Application to the US FDA Regarding A Two-Component Patellofemoral Implant System, the Episealer® Patellofemoral System, During 2021 Feb 19
Episurf Medical Receives Another Notice of Allowance from the United States Patent and Trademark Office Feb 06
Episurf Medical Announces New US Patent Approval within 3D Visualisation Feb 03
Episurf Medical AB (Publ) Promotes Michael Näsström as Head of Quality and Regulatory Affairs, Effective February 1, 2021 Jan 31 Episurf Medical Gets Approval for New US Patent
New Patent Approval in Hong Kong for Episurf Medical Jan 14
Episurf Medical AB (publ) Announces First Episealer Talus Surgery in the Asia-Pacific Jan 12
Episurf Medical Enters into Licensing Agreement of SEK 1.5 Million for µiFidelity Software Platform Dec 23
Episurf Medical Enters into Distribution Agreement with In2Bones SAS Dec 20
New 90-day high: €0.29 Dec 18
Episurf Medical AB (publ) Announces That Post-Market Surveillance Survival Data for the Episealer Dec 16
Independent Director recently bought €45k worth of stock Dec 16
Third quarter earnings released Oct 24
Third-quarter earnings released: Revenue in line with expectations Oct 24 Shareholder Returns 16E DE Medical Equipment DE Market 7D -96.7% -3.3% -2.0% 1Y -99.6% -8.5% 6.9%
See full shareholder returns
Return vs Market: 16E underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is 16E's price volatile compared to industry and market? 16E volatility 16E Average Weekly Movement 6,660.0% Medical Equipment Industry Average Movement 6.7% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 16E's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 16E's weekly volatility has increased from 6445% to 6660% over the past year.
About the Company Episurf Medical AB (publ), a medical device company, designs and manufactures implants and surgical instruments in Germany, Sweden, rest of Europe, the United States, and internationally. It offers Episealer Knee for repairing focal cartilage and bone defects to reduce pain and increase mobility in the patient’s knee joint; Episealer implant, which is designed to fit anatomy and size of the lesion; Episealer toolkit; and Episealer Patellofemoral System, a system to treat osteoarthritis limited to the patellofemoral part of the knee joint. The company also provides Episealer Talus, a solution for the treatment of bone and cartilage defects in the talus bone of the ankle joint; Epioscopy to identify and visualize femoral knee joint cartilage and bone lesions, and tibia, as well as defects on the cruciate ligaments and menisci; Epiguide, a surgical drill guide; and µiFidelity, a web platform for order management, communication, personalized design, and surgical pre-planning.
Show more Episurf Medical AB (publ) Fundamentals Summary How do Episurf Medical's earnings and revenue compare to its market cap? 16E fundamental statistics Market cap €6.90m Earnings (TTM ) -€6.94m Revenue (TTM ) €1.09m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 16E income statement (TTM ) Revenue SEK 12.50m Cost of Revenue SEK 51.50m Gross Profit -SEK 39.00m Other Expenses SEK 40.80m Earnings -SEK 79.80m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 05, 2025
Earnings per share (EPS) -0.12 Gross Margin -312.00% Net Profit Margin -638.40% Debt/Equity Ratio 0%
How did 16E perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 10:48 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Episurf Medical AB (publ) is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Patrik Ling DNB Markets Yilmaz Mahshid Pareto Securities Anders Hedlund Redeye
Show 1 more analysts 
